FDA Sheds Light On How It Will Gauge Pharmaceutical Quality During Inspections
Agency Says NIPP Protocols Will Be Expanded To Non-Sterile Drugs Next Year
The US FDA announces plans to expand its new protocol-based approach to inspections, NIPP, to non-sterile drugs and provides glimpse of what metrics the agency is using to measure pharmaceutical quality during inspections.
You may also be interested in...
US FDA expects the New Inspection Protocol Project (NIPP) it launched Nov. 9 to increase the consistency of its sterile manufacturing inspections – and the ability of those inspections to catch quality problems before they could lead to drug shortages.
US FDA touts new evidence that high performance of pharmaceutical manufacturing sites on 10 quality maturity metrics correlates with robust pharmaceutical quality systems, operational excellence and good business. An FDA-funded study by St. Gallen also finds that low performance, on the other hand, correlates with manufacturing problems.
Head of US FDA's Office of Pharmaceutical Quality says agency doesn't want pharmaceutical companies to know just how they will be inspected under the emerging standardized 'NIPP' approach, lest they use that knowledge to game the process.